SLC5A2 and type 2 diabetes mellitus: From baseline, albuminuria had decreased by 40% in the empagliflozin cohort, compared with only 18% in the sitagliptin cohort, bolstering the nephroprotective efficacy of sodium-glucose transport protein 2 (SGLT2) inhibitors in T2DM.